2272 related articles for article (PubMed ID: 787436)
1. Malignant melanoma.
Spitler LE
J Invest Dermatol; 1976 Sep; 67(3):435-41. PubMed ID: 787436
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy for human malignant melanoma.
Kopf AW
South Med J; 1975 Apr; 68(4):495-503. PubMed ID: 1124416
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapy of malignant melanoma.
Thiers BH
J Am Acad Dermatol; 1982 Apr; 6(4 Pt 1):559-62. PubMed ID: 6176602
[No Abstract] [Full Text] [Related]
4. Immunology and cutaneous malignant melanoma.
Sober AJ
Int J Dermatol; 1976; 15(1):1-18. PubMed ID: 1107238
[No Abstract] [Full Text] [Related]
5. Tumor-directed immune reactivity and immunotherapy in malignant melanoma. Current status.
Mavligit G; Gutterman JU; McBride C; Hersh EM
Prog Exp Tumor Res; 1974; 19():222-52. PubMed ID: 4612607
[No Abstract] [Full Text] [Related]
6. BCG immunotherapy of a mucous membrane malignant melanoma. Report of a case.
Pliskin ME; Mastrangelo MJ; Bellet R; Berkelhammer J
Oral Surg Oral Med Oral Pathol; 1976 Jul; 42(1):73-9. PubMed ID: 781579
[No Abstract] [Full Text] [Related]
7. [Development in the immunotherapy of malignant melanoma].
Tritsch H
Hautarzt; 1976 Jan; 27(1):1-7. PubMed ID: 767300
[TBL] [Abstract][Full Text] [Related]
8. [Immunologic reactions in malignant melanoma of the skin in man].
Veresova OV; Korosteleva TA
Vopr Onkol; 1975; 21(4):74-80. PubMed ID: 1105967
[No Abstract] [Full Text] [Related]
9. Immunology and immunotherapy of human-malignant melanoma: historic review and perspectives for the future.
Gutterman JU; Mavligit G; Reed R; Richman S; McBride CE; Hersh EM
Semin Oncol; 1975 Jun; 2(2):155-74. PubMed ID: 790574
[No Abstract] [Full Text] [Related]
10. [Immunotherapy].
Lejeune FJ; Bernheim JL; Vanwijck R
Acta Chir Belg; 1974 Mar; 73(2):265-93. PubMed ID: 4450923
[No Abstract] [Full Text] [Related]
11. Specific cytotoxic antibody in the sera of patients with melanoma.
Kilpatrick RJ; Seigler HF
J Surg Res; 1976 Nov; 21(5):301-5. PubMed ID: 794584
[No Abstract] [Full Text] [Related]
12. In vitro assay of cell-mediated immunity in BCG therapy of malignant melanoma: a preliminary report.
Nathanson L; Clark DA
Natl Cancer Inst Monogr; 1973 Dec; 39():221-4. PubMed ID: 4595321
[No Abstract] [Full Text] [Related]
13. Progress of immunotherapy in the treatment of malignant melanoma.
Ariyan S
Yale J Biol Med; 1975 Nov; 48(5):423-9. PubMed ID: 1108459
[No Abstract] [Full Text] [Related]
14. Immunotherapy of human malignant melanoma with irradiated tumor cells, oral Bacillus Calmette-Guérin, and levamisole.
Shibata HR; Jerry LM; Lewis MG; Mansell PW; Capek A; Marquis G
Ann N Y Acad Sci; 1976; 277(00):355-66. PubMed ID: 1069555
[No Abstract] [Full Text] [Related]
15. Active specific and active non-specific immunotherapy in patients with malignant melanoma.
Kokoschka EM; Cerni C; Micksche M
Oncology; 1977; 34(5):229-33. PubMed ID: 917456
[TBL] [Abstract][Full Text] [Related]
16. Antigen-reactive cells to tumor antigens in normal and tumor patients.
Falk RE; MacGregor AB
J Surg Res; 1976 Mar; 20(3):247-53. PubMed ID: 772313
[No Abstract] [Full Text] [Related]
17. BCG, levamisole and transfer factor in the treatment of cancer.
Spitler LE
Prog Exp Tumor Res; 1980; 25():178-92. PubMed ID: 6986631
[No Abstract] [Full Text] [Related]
18. Adjuvant therapy of cutaneous malignant melanoma: a critical review.
Koh HK; Sober AJ; Harmon DC; Lew RA; Carey RW
Med Pediatr Oncol; 1985; 13(5):244-60. PubMed ID: 3897817
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapy of human malignant melanoma with oil-attached BCG cell-wall skeleton.
Yamamura Y; Yoshizaki K; Azuma I; Yagura T; Watanabe T
Gan; 1975 Aug; 66(4):355-63. PubMed ID: 1102379
[TBL] [Abstract][Full Text] [Related]
20. Results of administering B.C.G. to patients with melanoma.
Grant RM; Mackie R; Cochran AJ; Murray EL; Hoyle D; Ross C
Lancet; 1974 Nov; 2(7889):1096-100. PubMed ID: 4139404
[No Abstract] [Full Text] [Related]
[Next] [New Search]